These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39082134)

  • 1. Relationship of Ketosis With Myocardial Glucose Uptake Among Patients Undergoing FDG PET/CT for Evaluation of Cardiac Sarcoidosis.
    Vidula MK; Selvaraj S; Rojulpote C; Bhattaru A; Kc W; Hansbury M; Schubert E; Clancy CB; Rossman M; Goldberg LR; Farwell M; Pryma D; Bravo PE
    Circ Cardiovasc Imaging; 2024 Aug; 17(8):e016774. PubMed ID: 39082134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of serum ketone levels for assessment of myocardial glucose suppression for
    Madamanchi C; Weinberg RL; Murthy VL
    J Nucl Cardiol; 2023 Jun; 30(3):928-937. PubMed ID: 36823484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-care β-hydroxybutyrate measurement predicts adequate glucose metabolism suppression in cardiac FDG-PET/CT.
    Hartikainen S; Tompuri T; Laitinen T; Laitinen T
    Clin Physiol Funct Imaging; 2024 Sep; 44(5):349-358. PubMed ID: 38587999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis.
    Lu Y; Grant C; Xie K; Sweiss NJ
    Clin Nucl Med; 2017 Feb; 42(2):88-94. PubMed ID: 27922863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis.
    Dweck MR; Abgral R; Trivieri MG; Robson PM; Karakatsanis N; Mani V; Palmisano A; Miller MA; Lala A; Chang HL; Sanz J; Contreras J; Narula J; Fuster V; Padilla M; Fayad ZA; Kovacic JC
    JACC Cardiovasc Imaging; 2018 Jan; 11(1):94-107. PubMed ID: 28624396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol.
    Christopoulos G; Jouni H; Acharya GA; Blauwet LA; Kapa S; Bois J; Chareonthaitawee P; Rodriguez-Porcel MG
    J Nucl Cardiol; 2021 Apr; 28(2):661-671. PubMed ID: 31111450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial.
    Selvaraj S; Margulies KB; Dugyala S; Schubert E; Tierney A; Arany Z; Pryma DA; Shah SH; Rame JE; Kelly DP; Bravo PE
    J Nucl Med; 2022 May; 63(5):770-776. PubMed ID: 34675108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies.
    Alfawara MS; Ahmed AI; Saad JM; Han Y; Alahdab F; Al Rifai M; Kassi M; Alnabelsi T; Zoghbi WA; Al-Mallah MH
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1103-1110. PubMed ID: 36474124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete resolution of focal-on-diffuse myocardial activity pattern on FDG PET-CT by prolonging the dietary preparation protocol in cardiac sarcoidosis.
    Kherajani P; Farag AA; Morgan WS; Hage FG; Bhambhvani P
    J Nucl Cardiol; 2023 Dec; 30(6):2525-2530. PubMed ID: 37524998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of newly diagnosed sarcoidosis in patients with ventricular arrhythmias: a cardiac magnetic resonance and 18F-FDG cardiac PET study.
    Kebed KY; Carter SV; Flatley E; Ward RP; Moss JD; Appelbaum DE; Singh A; Lang RM; Tung R; Patel AR
    Int J Cardiovasc Imaging; 2021 Apr; 37(4):1361-1369. PubMed ID: 33225427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis.
    Tahara N; Tahara A; Nitta Y; Kodama N; Mizoguchi M; Kaida H; Baba K; Ishibashi M; Hayabuchi N; Narula J; Imaizumi T
    JACC Cardiovasc Imaging; 2010 Dec; 3(12):1219-28. PubMed ID: 21163450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.
    Blankstein R; Osborne M; Naya M; Waller A; Kim CK; Murthy VL; Kazemian P; Kwong RY; Tokuda M; Skali H; Padera R; Hainer J; Stevenson WG; Dorbala S; Di Carli MF
    J Am Coll Cardiol; 2014 Feb; 63(4):329-36. PubMed ID: 24140661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter- and Intraobserver Agreement of
    Ohira H; Ardle BM; deKemp RA; Nery P; Juneau D; Renaud JM; Klein R; Clarkin O; MacDonald K; Leung E; Nair G; Beanlands R; Birnie D
    J Nucl Med; 2017 Aug; 58(8):1324-1329. PubMed ID: 28254873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive nutrient consumption estimation and metabolic profiling during ketogenic diet and relationship with myocardial glucose uptake on FDG-PET.
    Selvaraj S; Seidelmann SB; Soni M; Bhattaru A; Margulies KB; Shah SH; Dugyala S; Qian C; Pryma DA; Arany Z; Kelly DP; Chirinos JA; Bravo PE
    Eur Heart J Cardiovasc Imaging; 2022 Nov; 23(12):1690-1697. PubMed ID: 35366303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis.
    Shelke AB; Aurangabadkar HU; Bradfield JS; Ali Z; Kumar KS; Narasimhan C
    Int J Cardiol; 2017 Feb; 228():717-722. PubMed ID: 27886616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis.
    Manabe O; Yoshinaga K; Ohira H; Masuda A; Sato T; Tsujino I; Yamada A; Oyama-Manabe N; Hirata K; Nishimura M; Tamaki N
    J Nucl Cardiol; 2016 Apr; 23(2):244-52. PubMed ID: 26243179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Patient Preparation on the Diagnostic Performance of 18F-FDG PET in Cardiac Sarcoidosis: A Systematic Review and Meta-analysis.
    Tang R; Wang JT; Wang L; Le K; Huang Y; Hickey AJ; Emmett L
    Clin Nucl Med; 2016 Jul; 41(7):e327-39. PubMed ID: 26646995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent suppression of physiological myocardial FDG activity in patients with cardiac sarcoidosis.
    Sankaran SS; Kyprianou K; Cherk MH; Nadebaum DP; Beech PA; Khor R; Zimmet H; Hare JL; Larby A; Yap KS; Barber TW
    J Med Imaging Radiat Oncol; 2021 Feb; 65(1):54-59. PubMed ID: 33103345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis.
    Gormsen LC; Christensen NL; Bendstrup E; Tolbod LP; Nielsen SS
    J Nucl Cardiol; 2013 Dec; 20(6):1108-15. PubMed ID: 24132814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study.
    Gormsen LC; Svart M; Thomsen HH; Søndergaard E; Vendelbo MH; Christensen N; Tolbod LP; Harms HJ; Nielsen R; Wiggers H; Jessen N; Hansen J; Bøtker HE; Møller N
    J Am Heart Assoc; 2017 Feb; 6(3):. PubMed ID: 28242634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.